Epstein-barr virus-induced posttransplant lymphoproliferative disorders

Transplantation

Volumn 68, Issue 10, 1999, Pages 1517-1525

  Paya, Carlos V ^a   Fung, John J ^b   Nalesnik, Michael A ^c   Kieff, Elliott ^d   Green, Michael ^e   Gores, Gregory ^a   Habermann, Thomas M ^a   Wiesner, Russell H ^a   Swinnen, Lode J ^f   Woodle, E Steve ^g   Bromberg, Jonathan S ^h  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d HARVARD UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CHEMOTHERAPY; EPSTEIN BARR VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; VIRUS PATHOGENESIS;

EID: 0033610627     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911270-00015     Document Type: Article

References (68)

1. Starzl TE. Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immuno-suppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968; 168: 416.
2. Geis WP, Iwatsuki S, Molnar Z, et al. Pseudolymphoma in renal allograft recipients. Arch Surg 1978; 113: 461.
3. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
4. Hanto DW. Classification of Epstein-Barr virus associated post-transplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381.
5. Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8:139.
6. Morrison VA, Dunn DL, Manivel LC, Gail-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14.
7. Montone KT, Litzky LA, Wurster A, et al. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996; 119: 544.
8. Raymond E, Tricottet V, Samuel D, Reynes M, Bismuth H, Misset JL. Epstein-Barr Virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer 1995; 76: 1344.
9. Chen JM, Barr ML, Chadburn A, et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56: 527.
10. Penn I. The changing pattern of poststransplant malignancies. Transplant Proc 1991; 23: 1101.
11. Stephen SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118: 45.
12. Kieff E. Editorial: Epstein-Barr virus: new insights. J Infect Dis 1995; 171:1323.
13. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of Cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173.
14. Yandell DW, Li C, Saini S, et al. Brief report: lymphoma of donor origin occurring in the porta hepatis of a transplanted liver. N Engl J Med 1993; 329: 27.
15. Ho M, Breinig MK, Dummer JS, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary-infection. J Infect Dis 1985; 152: 876.
16. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
17. Cockfield SMA. Preiksaitis JK, Jewell LD, Parfrey NA. Post- transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993; 56: 88.
18. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346.
19. Mañez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462.
20. Vincenti F, Danovitch GM, Neylan JF, Steiner RW, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - a randomized, double-blind placebo-controlled study. Transplantation 1996; 61: 573.
21. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552.
22. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders (PTLD): Summary of Society for Hematopathology Workshop. Semin Diag Pathol. 1997; 14:8.
23. Lones MA, Lopez-Terrada D, Weiss LM, Shintaku IP, Said JW. Donor origin of posttransplant lymphoproliferative disorder localized to a liver allograft: demonstration by fluorescence in situ hybridization. Arch Pathol Lab Med 1997.
24. Glickman JN, Howe JG, Steitz JA. Structural analysis of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J Virol 1988; 62: 902.
25. Lister TA, Armitage JO. Non-Hodgkin's lymphomas. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical oncology. New York: Churchill Livingstone Inc., 1995: 2109.
26. Dockrell DH, Strickler JG, Paya CV. Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients. Clin Infect Dis 1998; 26: 180.
27. Lippman SM, Grogan TM, Carry P, et al. Posttransplantation T cell lymphoblastic lymphoma. Am J Med 1987; 82: 814.
28. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated posttransplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98.
29. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612.
30. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr Virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972.
31. Shipp M, Harrington D, Anderson J, et al. Development of a predictive model for aggressive lymphoma: the international NHL prognostic factors project. N Engl J Med 1993; 329: 997.
32. Penn I. Immunosuppression - a contributory factor in lymphoma formation. Clin Transplant 1992; 6: 214.
33. Benkerrow M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hemat Oncol Clin North Am 1993; 7: 467.
34. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; 1: 583.
35. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66: 1770.
36. O'Brien S, Bernert RA, Logan JL, Lien YH. Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Society Neph 1997; 8: 1483.
37. Hanto DW, Frizzera G, Galj-Peczalska, et al. Epstein Barr virus, immunodeficiency, and B-cell lymphoproliferation. Transplantation 1985; 39: 461.
38. Raymond E, Tricottet V, Samuel D, et al. Epstein-Barr virus-related lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1995; 72: 1344.
39. Lien Y-H, Schroter GPJ, Weil III R, et al. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant patient with acute pancreatitis. Transplantation 1991; 52: 739.
40. Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993; 72: 2782.
41. Swinnen LJ, Mullen GM, Carr, TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
42. vanGorp J, Doornewaard H, Verdonck LF, Klooping C, Vos PF, van den Tweel. Posttransplant T-cell lymphoma. Cancer 1994; 73: 3064.
43. Hanson MN, Morrison VA, Peterson BA, et al. Posttransplant T-cell lymphoproliferative disorders-an aggressive, late complication of solid-organ transplantation. Blood 1996; 88: 3626.
44. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451.
45. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961.
46. Benkerrou M, Jais JP, Leblond V, et al. Anti-B cell monoclonal antibody treatment of severe post-transplant B lymphoproliferative disorder: prognosis factors and long-term outcome. Blood 1998; 92: 3137.
47. Durandy A, Emilie D, Peuchmaur M, et al. Role of IL6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 1994; 152: 5361.
48. Boyle TJ, Berend KR, DiMaio, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 1993; 114: 218.
49. Papadopoulos EB, Ladany M, Emanuel D, et al. Infusion of donor leukocytes to treat Epstein-Barr Virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med, 1994; 330: 1185.
50. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 1: 9.
51. Emanuel DJ, Lucas KG, Mallory GB Jr, et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997; 63: 1691.
52. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63: 1200.
53. Franken M, Estabrooks A, Cavacini L, Sherburn B, Wang F, Scadden DT. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nature Med 1996; 2: 1379.
54. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240.
55. Stephan JL, Le Deist F, Blanche S, et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell specific monoclonal antibody. Transplantation 1992; 3: 83.
56. Durandy A, Le Deist F, Emile J-F, Debatin K, Fischer A. Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Eur J Immunol 1997; 27: 538.
57. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 1996; 61: 1279.
58. Green M, Kaufmann M, Wilson J, Reyes J Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of Cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 1344.
59. Darenkov IA, Marcarelli MM, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848.
60. Davis CL, Harrison KL, McVicar JP, Forg P, Bronner M, Marsh CL. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995; 9(1): 53.
61. Andersson J, Skoldenberg B, Enrberg I, Britton S, Henle W, Andersson U. Acyclovir treatment in primary Epstein-Barr virus infection. A double-blind placebo-controlled study. Scandinavian J Infect Dis 1985; 47: 107.
62. Lin JC, Smith MC. Pagano JS. Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus. Antimicrobial Agents Chemother 1985; 27: 971.
63. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB. Epstein-Barr virus-infected B cells persist in the circulation of acyclovirtreated virus carriers. Int J Cancer 1989; 43: 67.
64. Resnick L, Herbst JS, Ablashi DV, et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 1988; 259: 384.
65. Nadal D, Guzman J, Frohlich S, Braun DG. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation. Exp Hematol 1997; 25: 223.
66. Abedi MR, Linde A, Christensson B, Mackett M, Hammarstrom L, Smith CI. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Int J Cancer 1997; 71: 624.
67. Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998; 66: 1641.
68. McDiarmid SV, Jordan S, Lee, GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.